Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evinacumab in Homozygous Familial Hypercholesterolemia
2017-001388-19Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia comparing Evinacumab 15 mg/kg IV with Placebo IV (2 arms). Primary endpoint: Percent change in calculated LDL-C from baseline to week 24. Started Jan 2018; status: completed.
02
Drugs
evinacumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)hypercholesterolemia
Beyond the preview
Go deeper on 2017-001388-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001388-19.